By the Top Tier Newswire AI Desk · August 21, 2026 at 10:40 AM ET · reviewed against 1 wire stories
CRISPR THERAPEUTICS (CRSP) is up +6.56% in the latest session. Our newswire has captured 1 story on CRSP across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 42/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
CRSP stock rose 6.56% to $61.94 in a volatile session driven by a positive earnings surprise and a raised price target from Citigroup. The stock opened with a 1.1% gap up and reached a session high of $62.53 before closing near that level. The move came amid broader market momentum in biotech and gene-editing stocks.
What Happened
CRISPR Therapeutics reported Q2 earnings of $(0.94) per share, exceeding the estimated $(1.17) loss. Revenue for the quarter was $10.181 million, surpassing the expected $6.789 million. The results, while still unprofitable, demonstrated better-than-anticipated performance. Citigroup responded by maintaining its Buy rating on the stock and raising its price target to $88. The stock’s performance also aligned with broader pre-market trends in biotech, as noted in market reports. The session saw increased participation, with 0.8 million shares traded, or 0.5 times the 3-month average daily volume.
What The Data Shows
The stock has moved up 11.6% over the last 8 sessions, from $47.64 to $53.16. On 2026-08-21, the stock printed two fresh 52-week highs and two fresh 52-week lows, indicating a volatile market environment. Over the last 30 days, sentiment averaged 61 out of 100 but has declined to 42 over the past week. Recent insider transactions show one sale totaling $211,000 in the last 90 days, with the most recent filing on 2026-06-01.
What To Watch
The company is scheduled to report its next earnings release in the coming months. Investors should monitor coverage breadth for further analyst commentary and potential shifts in market sentiment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CRSP · Aug 21 session (5-min) · +2.46% vs prior close · updated 8:51 PM ETAI sentiment, last 36h · averaged over 1 story · 42/100 bearish
The headlines behind the move
Story flow · 1 story on the wire, last 36h · hover or tap a dot for the headline
22d agoThe Motley FoolBEARISH 42General
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?
This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →